NASDAQ$TRML
Tourmaline Bio Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported financial results and provided a business update, highlighting progress in clinical trials and pipeline advancement.
Talaris Therapeutics announced its Q3 2021 financial results, reporting a net loss of $12.9 million, or $0.32 per share. The company highlighted the initial clinical update from its Phase 3 FREEDOM-1 trial and the initiation of the Phase 2 FREEDOM-2 clinical trial.
- Provided initial clinical update from Phase 3 FREEDOM-1 trial evaluating FCR001 in living donor kidney transplant patients.
- Initiated Phase 2 FREEDOM-2 clinical trial for FCR001 in delayed tolerance induction patients.
- Presented updated long-term follow-up data from its Phase 2 LKDT study at the 2021 American Society of Nephrology meeting (ASN).
- Finished the third quarter of 2021 with $254.7 million in cash, cash equivalents and marketable securities.
Headline financials
Revenue & EPS history
Tourmaline Bio · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports
+0.7%
Avg return
Earnings day
-5.0%
Avg return
5 days after
+13.7%
Avg return
30 days after
59%
10 / 17 earnings
Positive
+11.6%
Q4 2023
Best reaction
-9.7%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +3.8% | +3.1% | +122.3% | |
| Q1 2025 | +4.6% | +9.9% | +26.5% | |
| Q4 2024 | -2.8% | -4.8% | -1.4% | |
| Q3 2024 | +5.0% | -4.9% | -5.6% | |
| Q2 2024 | +2.0% | +4.6% | +12.2% | |
| Q1 2024 | -0.6% | -4.8% | +2.6% | |
| Q4 2023 | +11.6% | -38.1% | -60.9% | |
| Q3 2023 | -1.2% | — | — | |
| Q2 2023 | +1.3% | — | — | |
| Q1 2023 | -8.0% | — | — | |
| Q4 2022 | +2.8% | — | — | |
| Q3 2022 | +7.0% | — | — | |
| Q2 2022 | -9.7% | — | — | |
| Q1 2022 | +3.1% | — | — | |
| Q4 2021 | +4.6% | — | — | |
| Q3 2021 | -7.0% | — | — | |
| Q2 2021 | -5.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro